Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:IMNM 15 December 2025 - 9 January 2026

Why Immunome stock is up today: IMNM jumps 7% as biotech firms up and JPM conference looms

Why Immunome stock is up today: IMNM jumps 7% as biotech firms up and JPM conference looms

Immunome shares rose 7.4% to $21.97 Friday after recent Phase 3 data showed its lead drug varegacestat cut disease progression or death by 84% in desmoid tumor patients. The company plans to file for FDA approval in Q2 2026. Immunome also granted stock options to three new hires and will present at the J.P. Morgan Healthcare Conference on Jan. 14.
9 January 2026
···
Immunome (IMNM) Stock Today: Phase 3 RINGSIDE Win, $400M Offering, and Fresh Analyst Targets (Dec. 16, 2025)

Immunome (IMNM) Stock Today: Phase 3 RINGSIDE Win, $400M Offering, and Fresh Analyst Targets (Dec. 16, 2025)

Immunome reported positive Phase 3 results for varegacestat in desmoid tumors, showing an 84% reduction in risk of progression or death versus placebo. The company also announced a proposed $400 million stock offering, raising concerns about dilution. Most side effects were mild, but 55.6% of premenopausal women experienced ovarian toxicity. Shares moved sharply on the news.
16 December 2025
··

Stock Market Today

  • Carter's (CRI) Shares Trade Slightly Below Fair Value Amid Mixed Returns
    March 19, 2026, 9:03 PM EDT. Carter's (CRI) shares closed at $35.04, just below the estimated fair value of $37.00 based on a detailed earnings and revenue model with an 11.78% discount rate. The stock showed a 1.54% gain over one day but experienced a 14.12% decline over 30 days and an 11.33% drop over one year, indicating longer-term pressure. Growth is limited by brand maturity and modest international expansion, especially outside markets like Brazil. Risks include competition from fast fashion and heavy reliance on baby apparel. Investors are advised to evaluate the company's revenue, margins, and earnings outlook closely before acting, as the share price may reflect cautious market expectations about future growth potential.
Go toTop